Creating long-lasting medications for HIV treatment
Prodrug Formulations Create Sustained-Release Antiretrovirals
This study is working on a new HIV medication that you could take just twice a year instead of every day, making it easier for you to stick to your treatment and stay healthy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-11085799 on NIH RePORTER |
What this research studies
This research focuses on developing new formulations of antiretroviral medications that can be administered less frequently, potentially every six months. By creating long-acting therapies, the goal is to improve patient adherence to treatment regimens and enhance overall health outcomes for individuals living with HIV. The research involves formulating a new drug, XVIR-110, which has already shown promise in safety studies and is moving towards clinical trials. Patients may benefit from a more convenient treatment schedule that reduces the need for frequent healthcare visits.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are seeking more manageable treatment options.
Not a fit: Patients who are not living with HIV or those who prefer traditional daily medication regimens may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with a more convenient and effective treatment option for managing HIV.
How similar studies have performed: Previous research has shown success with long-acting antiretroviral therapies, indicating a promising direction for this novel approach.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Edagwa, Benson — University of Nebraska Medical Center
- Study coordinator: Edagwa, Benson
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.